MedTrace Logo

Inflammation in COPD and the Effect of Nicotinamide Riboside

NCT04990869 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-03-15

No results posted yet for this study

Summary

The aim of this study is to investigate if nicotinamide riboside can reduce the airways inflammation associated with chronic obstructive pulmonary disease (COPD) in patients aged 60 or older. A major event in aging is the loss of the central metabolite nicotinamide adenine dinucleotide (NAD+) that appear to be important in the proinflammatory environment that occur during aging. Notably, recent work suggest that aging can be ameliorated by even a short-term treatment of the NAD+ precursor nicotinamide riboside. Nicotinamide riboside has recently been shown to be able to return aging tissues to a younger state even after short term treatment. This vitamin B3- analog is naturally occurring, is readily taken up through oral administration and has been tested in human trials with few side effects. The investigators hypothesize that six weeks of nicotinamide riboside supplementation reduces interleukin-8 measured in sputum from COPD patients. Further, it is hypothesized that augmentation of NAD+ in COPD patients might alleviate symptoms through activation of sirtuins.

Conditions

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside

The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • Bispebjerg Hospital

    collaborator OTHER

  • Elysium Health

    collaborator INDUSTRY

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Morten Scheibye-Knudsen, MD/DMSc(PhD) · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-05
Primary Completion
2022-08-18
Completion
2022-08-18

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04990869 on ClinicalTrials.gov